Study of an ALK-targeted drug for ALK-positive lung cancer
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) or, for a specific group, at least 12 years old and over 40 kg
- Your cancer has an ALK gene change (an ALK rearrangement or an activating ALK mutation) proven by an approved test
- For Phase 2 (most groups), your cancer is ALK-rearranged non-small cell lung cancer, or for the 2f group it can be another solid tumor
- Your cancer should be measurable (visible/trackable) on scans, depending on the phase of the trial
- Your organs and blood counts (bone marrow) must be strong enough for treatment
- Your cancer should not have another known major driver mutation besides ALK
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides early access to the drug neladalkib for people with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
This study tests a new drug called ALK201 combined with another drug (ivonescimab) to see if they are safe and help people with a type of lung cancer called squamous non-small cell lung cancer. If you join, you may receive the combination treatment and be closely monitored.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study tests a new combination cancer medicine (ALK202) for non-small cell lung cancer that hasn't responded to standard treatments. The goal is to see if this drug combination shrinks tumors and is safe to take.
Hear when a new Locally Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.